Literature DB >> 9129001

Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group.

K K Anbari1, L M Schuchter, L P Bucky, R Mick, M Synnestvedt, D Guerry, R Hamilton, A C Halpern.   

Abstract

BACKGROUND: A retrospective analysis of 40 patients diagnosed with melanoma of unknown primary site (MUP) was undertaken to analyze the etiology and clinical behavior of this presentation.
METHODS: The patient records were located by a computer search of the Pigmented Lesion Clinic data base at the University of Pennsylvania. With the Cox proportional hazards model, the survival of the MUP patients with lymph node presentation was compared with that of patients with lymph node disease and a known concurrent primary melanoma.
RESULTS: Sixty-five percent of the patients presented with lymph node metastasis only, 28% presented with visceral lesions, and 8% presented with subcutaneous nodules. The prevalence of dysplastic nevi was 22.5%. The overall 4-year survival rate for the 40 MUP patients was 55% +/- 9%. The 4-year survival (57% +/- 12%) of patients with lymph node presentation was compared with that of patients presenting with lymph node disease and a known concurrent primary melanoma (19 +/- 6%). Survival was significantly different between the groups (P = 0.008). This survival difference remained significant (P = 0.02) even after adjustments for number of positive lymph nodes, year of diagnosis, and age at diagnosis.
CONCLUSIONS: This analysis revealed that MUP patients with lymph node metastasis survived significantly longer than patients diagnosed with lymph node metastasis concurrent with a known cutaneous primary melanoma. The prevalence of dysplastic nevi in the MUP patient series was intermediate between that reported among primary melanoma patients and that reported among population controls, suggesting the likelihood of a primary cutaneous origin for the metastatic melanoma.

Entities:  

Mesh:

Year:  1997        PMID: 9129001     DOI: 10.1002/(sici)1097-0142(19970501)79:9<1816::aid-cncr26>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation.

Authors:  Gabriela I Rozenberg; Kimberly B Monahan; Chad Torrice; James E Bear; Norman E Sharpless
Journal:  Melanoma Res       Date:  2010-10       Impact factor: 3.599

2.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

3.  Amelanotic melanoma presenting with cervical lymphadenopathy.

Authors:  Abhishek Karnwal; Edward Hadjihannas; Ali Sherif; Simon Grumett; Sudha Karnwal; John Mathews
Journal:  BMJ Case Rep       Date:  2009-04-07

4.  Management decisions for nodal metastasis from an unknown primary melanoma.

Authors:  Chris C Lee; Mark B Faries; Donald L Morton
Journal:  Am J Hematol Oncol       Date:  2008-07-01

5.  Malignant gastrointestinal melanoma with an unknown primary.

Authors:  M V T Krishna Mohan; Senthil J Rajappa; T Vamshidhar Reddy; T Roshni Paul
Journal:  Indian J Med Paediatr Oncol       Date:  2009-04

6.  Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.

Authors:  Kenichiro Kakutani; Minoru Doita; Kotaro Nishida; Hiroshi Miyamoto; Masahiro Kurosaka
Journal:  Eur Spine J       Date:  2007-12-13       Impact factor: 3.134

7.  Improved survival for stage IV melanoma from an unknown primary site.

Authors:  Chris C Lee; Mark B Faries; Leslie A Wanek; Donald L Morton
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

9.  Melanoma of unknown origin: a case series.

Authors:  J Kelly; H P Redmond
Journal:  Ir J Med Sci       Date:  2009-07-29       Impact factor: 1.568

10.  Solitary dermal melanoma: beginning or end of the metastatic process?

Authors:  Chris C Lee; Mark B Faries; Xing Ye; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-01-06       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.